



# **Comparative Study Between Platelet Rich Plasma and Minoxidil in The Treatment of Alopecia Totalis**

Thesis

*Submitted for Partial Fulfillment of The Master  
Degree in Dermatology, Venereology and Andrology*

Presented by

**Dina Hesham Adel Nour El din**

*M.B.B.Ch. Faculty of Medicine - Ain Shams University*

Under the Supervision of

**Prof. Dr. Hanan Mohamed El Kahky**

*Professor of Dermatology, Venereology and Andrology  
Faculty of Medicine - Ain Shams University*

**Dr. Azza Esmat Mostafa**

*Lecturer of Dermatology, Venereology and Andrology  
Faculty of Medicine - Ain Shams University*

*Department of Dermatology, Venereology and Andrology  
Faculty of Medicine - Ain Shams University*

**2017**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and  
profound gratitude to **Prof. Dr. Hanan  
Mohamed El Kahky**, Professor of Dermatology,  
Venereology and Andrology, Faculty of Medicine -  
Ain Shams University, her keen guidance, kind  
supervision, valuable advice and continuous  
encouragement, which made possible the completion  
of this work.*

*I am also delighted to express my deepest  
gratitude and thanks to **Dr. Azza Esmat  
Mostafa**, Lecturer of Dermatology ,Venereology  
and Andrology, Faculty of Medicine - Ain Shams  
University, for her kind care, continuous  
supervision, valuable instructions, constant help  
and great assistance throughout this work.*

*I would like to express my hearty thanks to all  
my family for their support till this work was  
completed.*

*Last but not least my sincere thanks and  
appreciation to all patients participated in this  
study.*

***Dina Hesham Adel Mour El din***

# *List of Contents*

Title	Page No.
List of Tables .....	5
List of Figures .....	7
List of Abbreviations .....	9
Introduction .....	1
Aim of the Work.....	4
<b>Review of Literature</b>	
▪ Alopecia Areata.....	5
▪ Platelet Rich Plasma .....	38
▪ Minoxidil .....	60
Patients and Methods .....	71
Results .....	84
Case Presentation .....	104
Discussion .....	110
Summary .....	120
Conclusion.....	123
Recommendations .....	124
References .....	125
Arabic Summary	

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Platelet rich plasma therapy preparatory systems .....	45
<b>Table (2):</b>	Description and comparison between group A and B cases as regard personal and medical data.....	85
<b>Table (3):</b>	Dermoscopic parameters at baseline, at 3 months after treatment and the difference between the 2 readings among group A cases .....	89
<b>Table (4):</b>	Comaprison between dermoscopic parameters before and after end of treatment among group A cases .....	90
<b>Table (5):</b>	Dermoscopic parameters at baseline, at 3 months after treatment and the difference between the 2 readings among group B cases	94
<b>Table (6):</b>	Comparison of dermoscopic parameters before and after end of treatment among group B cases	95
<b>Table (7):</b>	Comparison of dermoscopic parameters of group A and B cases at baseline, at 3 months and the difference between them.....	98
<b>Table (8):</b>	Clinical improvement among group A and group B cases.....	100
<b>Table (9):</b>	Mean SALT score at baseline, at 3 months after treatment and the difference between them in group A cases .....	101
<b>Table (10):</b>	Comparison of SALT score at baseline and after 3 months among group A cases.....	101

## *List of Tables (cont...)*

Table No.	Title	Page No.
<b>Table (11):</b>	Mean SALT score at baseline, at 3 months after and the difference between the 2 readings in group B cases.....	102
<b>Table (12):</b>	Comparison of SALT score at baseline and after 3 months treatment among group B cases .....	102
<b>Table (13):</b>	Comparison of SALT score between group A and group B at baseline and at 3 months and the difference between them.....	103

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Hair growth cycle .....	8
<b>Figure (2):</b>	Pathogenesis of alopecia areata .....	12
<b>Figure (3):</b>	Patchy alopecia areata. ....	17
<b>Figure (4):</b>	Alopecia totalis.....	17
<b>Figure (5):</b>	Histopathology of alopecia areata .....	27
<b>Figure (6):</b>	Dystrophic hair shafts and yellow dots .....	28
<b>Figure (7):</b>	Exclamation marks and black dots .....	28
<b>Figure (8):</b>	Flowchart illustrating preparation of "activated PRP" .....	51
<b>Figure (9):</b>	Ycell bio separation kit. ....	79
<b>Figure (10):</b>	Collection of blood in Ycell Tube.....	80
<b>Figure (11):</b>	80-2A centrifuge. ....	80
<b>Figure (12):</b>	Separated PRP.....	81
<b>Figure (13):</b>	3 and 5 ml of PRP and PPP.....	81
<b>Figure (14):</b>	Dermoscope attached to the laptop. ....	82
<b>Figure (15):</b>	Mean age of patients and mean duration of alopecia totalis in group A and B cases. ....	85
<b>Figure (16):</b>	Mean number of yellow dots and black dots at baseline and after 3 months of end of PRP treatment in group A. ....	90
<b>Figure (17):</b>	Mean number of vellus hair and terminal hair at baseline and after 3 months of end of PRP treatment in group A. ....	91
<b>Figure (18):</b>	Mean yellow dot number and black dot number at baseline and at 3 months after treatment with intradermal minoxidil 2 % in group B. ....	95

## *List of Figures (cont...)*

Fig. No.	Title	Page No.
<b>Figure (19):</b>	Mean broken hair number and tapering hair number at baseline and at 3 months after treatment with intradermal minoxidil 2 % in group B. ....	96
<b>Figure (20):</b>	Mean vellus hair number and terminal hair number at baseline and at 3 months after treatment with intradermal minoxidil 2% in group B. ....	96
<b>Figure (21):</b>	Clinical Case (1).....	104
<b>Figure (22):</b>	Clinical Case (2).....	105
<b>Figure (23):</b>	Clinical Case (3).....	106
<b>Figure (24):</b>	Clinical Case (4).....	107
<b>Figure (25):</b>	Clinical Case (5).....	108
<b>Figure (26):</b>	Clinical Case (6).....	109



## *List of Abbreviations*

<i>Abb.</i>	<i>Full term</i>
<i>AA</i> .....	<i>Alopecia areata.</i>
<i>PRP</i> .....	<i>Platelet rich plasma.</i>
<i>CD</i> .....	<i>Cluster of differentiation.</i>
<i>NK</i> .....	<i>Natural killer.</i>
<i>HLA</i> .....	<i>Human leucocytic antigen.</i>
<i>MHC</i> .....	<i>Major histocompatibility complex.</i>
<i>JAK</i> .....	<i>Janus Kinase.</i>
<i>SALT</i> .....	<i>Severity of alopecia tool score.</i>
<i>PPP</i> .....	<i>Platelet poor plasma.</i>
<i>P-PRP</i> .....	<i>Platelet pure rich plasma.</i>
<i>L-PRP</i> .....	<i>Leucocyte rich platelet rich plasma.</i>
<i>FDA</i> .....	<i>Food and drug administration approved.</i>
<i>HE</i> .....	<i>Hematoxylin and eosin.</i>

## **Abstract**

Our results showed no significant clinical improvement with PRP treatment, however dermoscopic features showed significantly improvement after PRP compared to minoxidil so we suggest that PRP treatment in alopecia totalis could be of benefit as adjuvant therapy in addition to the main treatment of alopecia totalis.

We highly recommend using dermoscope as an advanced aid in clinical dermatological diagnosis and a great follow up tool.

Further studies are still recommended on a large number of patients in a trial to identify more uses of dermoscope and more medications to treat alopecia totalis.

**Keywords:** - *Major histocompatibility complex- Cluster of differentiation- Platelet rich plasma- Alopecia areata- Leucocyte rich platelet rich plasma- Hematoxylin and eosin*

## INTRODUCTION

Alopecia areata (AA) is a relatively common inflammatory disorder causing patches of non scarring hair loss (*Madani and Shapiro, 2000*).

Although the pathogenesis is not fully understood, considerable evidence suggests that autoimmune attack of the hair follicles causes alopecia areata (*Alexis et al., 2004*).

Most patients with AA have a mild disease consisting of several alopecia patches that regrow hair within a year. However, a subset of up to 10% of patients with AA have a prolonged disease course progressing to complete loss of scalp hair (alopecia totalis) or scalp and body hair (alopecia universalis) (*Gilhar and Kalish, 2006*).

This extreme hair loss results in cosmetic disfigurement that may contribute to psychosocial abnormalities such as anxiety, depression, lack of self-confidence, and poor overall mental health (*Güleç et al., 2004*).

The management of AA involves both addressing the psychological needs of the patient and offering treatment to patients who desire intervention. A variety of topical, intralesional, and systemic agents, as well as devices, have been used for alopecia, but the response to treatment varies widely, and few well-designed clinical trials have evaluated these therapies.

The choice of therapy depends primarily on the patient's age and the extent of the hair loss (*Delamere et al., 2008*).

A non-specific treatment modality for AA is minoxidil, which prolongs anagen phase and promotes growth of longer and wider hair. These treatments stimulate hair growth but do not prevent hair loss and probably do not influence the course of the disease (*Shapiro and Price, 1998*).

Recently, autologous platelet-rich plasma (PRP) has attracted attention in various medical fields, including plastic and orthopedic surgery and dermatology, for its ability to promote wound healing. PRP has been tested during facelift and hair transplantation to reduce swelling and pain and to increase hair density (*Li et al., 2012*).

Platelet Rich Plasma is defined as a sample of autologous blood with concentrations of platelets above baseline values. Platelets play an instrumental role in the normal healing response via the local secretion of growth factors and recruitment of reparative cells (*Eppley et al., 2004*).

A significant improvement in hair density and stimulation of growth was observed when follicular units were pretreated with platelet plasma growth factors before their implantation. It was hypothesized that growth factors released from platelets may act on stem cells in the bulge area of the

follicles, stimulating the development of new follicles and promoting neovascularization (*Cervelli et al., 2009*).

There are scarce reports in the literature about the effect of PRP on hair growth.

## **AIM OF THE WORK**

The aim of the current thesis was to assess the role of PRP in the treatment of alopecia totalis as compared to intradermal minoxidil 2%.

## Chapter 1

# ALOPECIA AREATA

Alopecia areata(AA) is a complex genetic, immune mediated disease that affects anagen hair follicles. The disease affects children and adults, males and females, and people of all ages and races. AA can be a chronic relapsing disorder that results in non-scarring hair loss of which there are three major clinical presentations (*Hordinsky, 2013*).

Localized AA is characterized by round or oval patches of non-scarring hair loss in any hair bearing area. A subset of 10% of AA patients may advance to loss of all scalp hair (alopecia totalis) or all body hair (alopecia universalis) or ophiasis hair loss, but many patients may present anywhere along the spectrum from patchy to total body hair loss (*Messenger et al., 2012*).

Not all patients may require treatment, as up to 50 % of patients with limited disease of less than 1 year duration can experience spontaneous hair re-growth (*Hordinsky, 2011*).

Commonly associated diseases include asthma, allergic rhinitis, atopic dermatitis, thyroid disease, and autoimmune diseases, such as thyroiditis and vitiligo (*Messenger et al., 2012*).

Alopecia areata has a variety of clinical courses, and it is not easy for clinicians to predict prognosis and clinical outcome of each patient. However, several epidemiologic studies on